UA99936C2 - Biaryl substituted azabicyclic alkane derivatives - Google Patents

Biaryl substituted azabicyclic alkane derivatives

Info

Publication number
UA99936C2
UA99936C2 UAA201007604A UAA201007604A UA99936C2 UA 99936 C2 UA99936 C2 UA 99936C2 UA A201007604 A UAA201007604 A UA A201007604A UA A201007604 A UAA201007604 A UA A201007604A UA 99936 C2 UA99936 C2 UA 99936C2
Authority
UA
Ukraine
Prior art keywords
alkane derivatives
biaryl substituted
substituted azabicyclic
azabicyclic alkane
biaryl
Prior art date
Application number
UAA201007604A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цзяньго ЦЗИ
Тао ЛИ
Кевин Б Сиппи
Чих-хунг ЛИ
Мурали ГОПАЛАКРИШНАН
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA99936C2 publication Critical patent/UA99936C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Abstract

Изобретение касается биарилзамещенных производных азабициклических алканов, композиций, которые включают такие соединения, и способов лечения состояний и нарушений с использованием таких соединений и композиций.
UAA201007604A 2007-11-21 2008-11-20 Biaryl substituted azabicyclic alkane derivatives UA99936C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98953807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
UA99936C2 true UA99936C2 (en) 2012-10-25

Family

ID=40263587

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201007604A UA99936C2 (en) 2007-11-21 2008-11-20 Biaryl substituted azabicyclic alkane derivatives

Country Status (21)

Country Link
US (2) US7902222B2 (ru)
EP (2) EP2280010B1 (ru)
JP (2) JP5693229B2 (ru)
KR (1) KR20100090706A (ru)
CN (1) CN101925599A (ru)
AU (1) AU2008326360A1 (ru)
BR (1) BRPI0820418A2 (ru)
CA (1) CA2705296A1 (ru)
CO (1) CO6280476A2 (ru)
CR (1) CR11522A (ru)
DO (1) DOP2010000149A (ru)
EC (1) ECSP10010296A (ru)
GT (1) GT201000146A (ru)
IL (1) IL205763A0 (ru)
MX (1) MX2010005648A (ru)
NZ (1) NZ585055A (ru)
RU (1) RU2010125121A (ru)
SG (1) SG186018A1 (ru)
UA (1) UA99936C2 (ru)
WO (1) WO2009067579A1 (ru)
ZA (1) ZA201003289B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP2431368B1 (en) * 2006-05-19 2014-08-27 AbbVie Bahamas Ltd. CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
EP2280010B1 (en) * 2007-11-21 2012-12-19 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
FR2937641A1 (fr) 2008-10-28 2010-04-30 Sanofi Aventis Derives d'urees de tropane, leur preparation et leur application en therapeutique
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
MX2012008082A (es) * 2010-01-11 2013-02-07 Astraea Therapeutics Llc Moduladores del receptor nicotinico de acetilcolina.
AU2011256287B2 (en) 2010-05-17 2016-11-10 Envivo Pharmaceuticals, Inc. A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
WO2014164682A1 (en) 2013-03-12 2014-10-09 Abbvie Inc. Azaadamantane formate ester and process preparing azaadamantane derivatives
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
JP6850453B2 (ja) * 2015-11-10 2021-03-31 国立大学法人九州大学 ジシアノピラジン化合物、発光材料、およびそれを用いた発光素子
BR122020005073A2 (pt) 2017-08-04 2020-10-13 Skyhawk Therapeutics, Inc. Composto, composição farmacêutica e uso do composto
CN109593088B (zh) * 2018-12-27 2022-03-25 华东理工大学 氮杂双环衍生物及其制备和应用
CN113660936A (zh) * 2019-02-04 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0714394B1 (en) * 1993-08-19 2001-06-20 Novo Nordisk A/S Antipsychotic method with thiadiazole and oxadiazole derivatives
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
EP1185513A2 (en) * 1999-05-24 2002-03-13 Targacept, Inc. Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
US7148236B2 (en) * 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006101745A2 (en) * 2005-03-18 2006-09-28 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
TW200806662A (en) * 2005-12-01 2008-02-01 Organon Nv 8-azabicyclo[3.2.1]octane derivatives
EP2431368B1 (en) * 2006-05-19 2014-08-27 AbbVie Bahamas Ltd. CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
EP2280010B1 (en) * 2007-11-21 2012-12-19 Abbott Laboratories Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators

Also Published As

Publication number Publication date
CA2705296A1 (en) 2009-05-28
CR11522A (es) 2010-08-12
RU2010125121A (ru) 2011-12-27
CN101925599A (zh) 2010-12-22
CO6280476A2 (es) 2011-05-20
IL205763A0 (en) 2010-11-30
US8853241B2 (en) 2014-10-07
JP2015110583A (ja) 2015-06-18
BRPI0820418A2 (pt) 2015-05-19
US7902222B2 (en) 2011-03-08
AU2008326360A1 (en) 2009-05-28
US20110124676A1 (en) 2011-05-26
EP2280010B1 (en) 2012-12-19
ZA201003289B (en) 2012-10-31
EP2231657A1 (en) 2010-09-29
JP2011504181A (ja) 2011-02-03
EP2280010A3 (en) 2011-05-04
MX2010005648A (es) 2010-06-02
DOP2010000149A (es) 2010-06-30
GT201000146A (es) 2012-04-19
ECSP10010296A (es) 2010-07-30
US20090192186A1 (en) 2009-07-30
SG186018A1 (en) 2012-12-28
EP2280010A2 (en) 2011-02-02
KR20100090706A (ko) 2010-08-16
NZ585055A (en) 2012-07-27
WO2009067579A1 (en) 2009-05-28
JP5693229B2 (ja) 2015-04-01

Similar Documents

Publication Publication Date Title
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
MY147661A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
MY148253A (en) Azaadamantane derivatives and methods of use
IN2012DN03883A (ru)
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2010007392A (es) Antagonistas de trpa1.
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX2010007391A (es) Antagonistas de trpa1.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
MX2013001612A (es) Moduladores de trpv3 novedosos.
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.